A preliminary study of the clinical significance of folate receptor-positive circulating tumor cell in the management of hepatobiliary-pancreatic cancers.

Autor:	He YG; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing, China., Zheng L; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing, China., Gao MF; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing, China., Tang YC; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing, China., Li YM; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing, China., Yu KH; Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China., Li J; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing, China., Huang XB; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing, China.
Jazyk:	angličtina
Zdroj:	Translational cancer research [Transl Cancer Res] 2020 Nov; Vol. 9 (11), pp. 6700-6709.
DOI:	10.21037/tcr-20-2192
Abstrakt:	Background: Hepatobiliary-pancreatic cancers (HBPs) are highly lethal, partly because of their usually late diagnosis. This multi-center, observational study aimed to explore the clinical significance of folate receptor-positive circulating tumor cell (FR+CTC) as a liquid biopsy approach in the differential diagnosis and management of HBPs. Methods: We recruited 119 patients suspicious for HBPs and 60 cancer-free healthy individuals in the present study. Patients without definitive pathological assessment or without pre-operative FR+CTC analysis were excluded. FR+CTC was tested prior to surgery or tissue biopsy using the CytoploRare ® Detection Kit. Serum biomarkers, including CA 125, CA 19-9, and CEA, were tested in selected patients. Post-operative FR+CTC analysis was also performed in a subset of the patients receiving surgical resection. Results: With 8.65 FU/3 mL as the cut-off value, the sensitivity and specificity of FR+CTC in differential diagnosis were 98.1% and 79.1%, respectively. The detection rate of FR+CTC was superior to conventional serum biomarkers (CA 19-9 > CA 125 > CEA). For the 16patients with matched post-operative FR+CTC analysis, FR+CTC levels significantly reduced after surgery (P=0.0084). Conclusions: Our results demonstrated that FR+CTC analysis could be an efficacious non-invasive biomarker in differential diagnosis and surveillance of HBPs, though further investigation with a larger sample size is required. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-2192). The authors have no conflicts of interest to declare. (2020 Translational Cancer Research. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu